Causal Modeling of TCGA NSCLC and HNSCC Data Identifies Network Drivers of Tumor Immune Subtypes
Results of GNS Healthcare study of TCGA data presented at ASCO-SITC
Learn more about our novel use of causal AI to classify tumors based on their ability to respond to immune checkpoint inhibitor therapy.
Identifying the biomarkers for ICI response opens the door to numerous applications in the oncology space including:
- Enabling a personalized approach to patient care by delivering the right ICI therapy to the right patient
- Selecting optimal patient subpopulations for clinical trials based on likelihood of response
- Turning nonresponsive tumors (cold) into responsive tumors (hot)
- Uncovering areas new opportunities for drug development